History

2022
Merger of GenoBio Corp. and ExoTDX Corp
GenoCTC V5 development completed
2021
ExoTDX Corp. provides Exo-FAST to Harvard Medical School
2020
Publication - An Immune-Magnetophoretic Device for the Selective
and Precise Enrichment of Circulating Tumor Cells from Whole
Blood (Micromachines (Basel). 2020 May 30;11(6):560
2019
GenoCTC Version3 Item approval (Class 1)
2018
Approval of EpCAM-positive cell separation kit (Class 2)
GMP certification for in vitro diagnostic medical device reagent
production (Class 2)
Copyright agreement with Gencurix for products and services in Asia
2017
GenoCTC Version2 FCC, CE certified
Genobio-Deepbio integrated prostate cancer diagnosis system development agreement
2016
Ministry of Trade, Industry and Energy's selection of commercialization-
linked technology development
Venture Business Certification (No. 2020107264)
Medical device production GMP certification (Class 1)
Signed a strategic alliance with Genobio-Genocurix for "liquid biopsy"
2015
Selected as the 3rd general manager of the anticancer drug companion diagnosis project (source technology
2014
Established Genobio with the goal of developing a circulating tumor
cell isolation system